<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01570309</url>
  </required_header>
  <id_info>
    <org_study_id>AHA Award #0885041N</org_study_id>
    <nct_id>NCT01570309</nct_id>
  </id_info>
  <brief_title>Vitamin D Repletion in Coronary Artery Disease</brief_title>
  <official_title>The Effects of Vitamin D Repletion on Endothelial Function and Inflammation in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seth I. Sokol, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jacobi Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York City Health and Hospitals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D (Vit D) status is an emerging risk marker of great interest in cardiovascular
      disease (CVD). Lower serum levels of Vit D are associated with both cardiac risk factors and
      prevalent cardiovascular disease. Vit D insufficiency remains very prevalent in free living
      populations in the United States especially in urban, and multi-ethnic low income Northern
      cities.To date, prospective randomized trials using Vit D supplementation to modify CVD risk
      and evaluate outcomes have not been performed.

      The investigators propose a double-blind, randomized wait-list control trial in subjects with
      Coronary Artery Disease (CAD) and Vit D deficiency with two specific aims. Specific aim 1 is
      to measure endothelial function using reactive hyperemia peripheral arterial tonometry
      (RH-PAT) before and after treatment with Vit D replacement therapy. Specific Aim 2 is to
      measure levels of inflammation before and after treatment with Vit D replacement therapy.
      These aims will test the hypotheses that Vit D repletion will improve endothelial function
      and reduce the levels of detectable inflammation in the plasma of these subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 subjects with angiographically documented CAD and Vit D deficiency will be randomized to
      50,000 IU oral ergocalciferol (active treatment group) or placebo (delayed intervention
      group) once a week for 12 weeks. The investigators will measure endothelial function at
      randomization and week 12 using RH-PAT and serologically measured adhesion molecules (s-VCAM,
      s-ICAM, soluble e-selectin). Changes in levels of plasma cytokines and chemokines
      representing a T-cell activation pathway (IL-12, IFN-g and CXCL-10 - &quot;IFN-g axis&quot;) the
      investigators have linked to coronary atherogenesis (independent of CRP) and poor CV
      outcomes, will be measured over the 12 week study period. Given published evidence showing
      that Vit D can influence this T- cell pathway, specific aim 2 will add mechanistic insights
      to this proposal. High sensitivity C-reactive protein (hs-CRP) will be measured as it is a
      well established traditional marker of inflammation in CAD and has also been linked to Vit D
      status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Endothelial function was measured using peripheral arterial tonometry expressed as the reactive hyperemia index. The index is derived from the ratio of the post-to-pre occlusion peripheral arterial tonometry signal amplitude of the tested arm, divided by the post -to-pre occlusion ratio of the control arm. Median within subject change in endothelial function as measured by reactive hyperemia peripheral arterial tonometry index in each group is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammation -</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Median within subject change in hs-CRP levels between baseline and week 12 in active and placebo groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Median within subject change in interferon-gamma levels between baseline and week 12 in active and placebo groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Median within subject change in cxcl-10 .levels between baseline and week 12 in active and placebo groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Median within subject change in IL-12 levels between baseline and week 12 in active and placebo groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Ergocalciferol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50,000 units of ergocalciferol once a week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergocalciferol</intervention_name>
    <description>Oral capsule, 50,000 units, once a week, 12 weeks</description>
    <arm_group_label>Ergocalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>Oral capsule, once a week, 12 weeks</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and nonpregnant females greater than 18 years of age

          -  ≥ 50% angiographic stenosis of at least 1 coronary artery or documented previous
             revascularization

          -  Serum 25-hydroxyvitamin D &lt; 20 ng/ml

        Exclusion Criteria:

          -  confinement to a nursing facility, institution or home

          -  GFR &lt; 60 ml/min (by MDRD equation)

          -  presence of liver disease

          -  hypercalcemia

          -  NYHA class III or IV heart failure

          -  cardiogenic shock at time of presentation

          -  current planned or emergent CABG

          -  prior gastric or small bowel surgery

          -  pancreatitis

          -  malabsorption

          -  inflammatory bowel disease

          -  autoimmune disease

          -  active malignancy

          -  current use of &gt; 800 IU/day of vitamin D

          -  Current use of dilantin, phenobarbitol, immunosuppressant, or immunostimulant therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seth I Sokol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jacobi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center / Weiler division</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sokol SI, Srinivas V, Crandall JP, Kim M, Tellides G, Lebastchi AH, Yu Y, Gupta AK, Alderman MH. The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease. Vasc Med. 2012 Dec;17(6):394-404. doi: 10.1177/1358863X12466709. Erratum in: Vasc Med. 2013 Feb;18(1):51. Lebastchi, Amir [corrected to Lebastchi, Amir H].</citation>
    <PMID>23184900</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2012</study_first_submitted>
  <study_first_submitted_qc>April 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2012</study_first_posted>
  <results_first_submitted>September 23, 2012</results_first_submitted>
  <results_first_submitted_qc>August 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2013</results_first_posted>
  <last_update_submitted>August 5, 2013</last_update_submitted>
  <last_update_submitted_qc>August 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>New York City Health and Hospitals Corporation</investigator_affiliation>
    <investigator_full_name>Seth I. Sokol, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>vitamin D,</keyword>
  <keyword>vitamin D deficiency</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>ergocalciferol</keyword>
  <keyword>endothelial function</keyword>
  <keyword>adhesion molecules</keyword>
  <keyword>inflammation</keyword>
  <keyword>IL-12</keyword>
  <keyword>interferon-gamma</keyword>
  <keyword>CXCL-10</keyword>
  <keyword>reactive hyperemia peripheral arterial tonometry</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>cytokines</keyword>
  <keyword>chemokines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment from October 2008 through December 2010 from the cardiac catheterization laboratories and outpatient clinics of the Jacobi Medical Center and Montefiore Medical Center in the Northeastern section of the Bronx, NY. Additional recruitment occurred at Crystal Run Health in Orange County, NY.</recruitment_details>
      <pre_assignment_details>Subjects with ≥ 50% angiographic stenosis of at least 1 coronary artery or documented previous revascularization, were screened for vitamin D deficiency by measurement of serum 25-hydroxyvitamin D (25-vitamin D).Eligible subjects with a 25-vitamin D level &lt; 20 ng/ml were randomly assigned 1:1 to active or placebo treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ergocalciferol</title>
          <description>50,000 units of ergocalciferol once a week for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Matching placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ergocalciferol</title>
          <description>50,000 units of ergocalciferol once a week for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Matching placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="9.5"/>
                    <measurement group_id="B2" value="56.5" spread="11.7"/>
                    <measurement group_id="B3" value="55.6" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endothelial Function</title>
        <description>Endothelial function was measured using peripheral arterial tonometry expressed as the reactive hyperemia index. The index is derived from the ratio of the post-to-pre occlusion peripheral arterial tonometry signal amplitude of the tested arm, divided by the post –to-pre occlusion ratio of the control arm. Median within subject change in endothelial function as measured by reactive hyperemia peripheral arterial tonometry index in each group is presented.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Assuming a standard deviation of 0.6 in the change in RH-PAT score from baseline to 12 weeks, we estimated that the study would need a sample size of 45 patients per treatment group to have 80% power at a two tailed alpha=0.05 level to detect a minimum difference in change in RH-PAT score of 0.36 between treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Ergocalciferol</title>
            <description>50,000 units of ergocalciferol once a week for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Function</title>
          <description>Endothelial function was measured using peripheral arterial tonometry expressed as the reactive hyperemia index. The index is derived from the ratio of the post-to-pre occlusion peripheral arterial tonometry signal amplitude of the tested arm, divided by the post –to-pre occlusion ratio of the control arm. Median within subject change in endothelial function as measured by reactive hyperemia peripheral arterial tonometry index in each group is presented.</description>
          <population>Assuming a standard deviation of 0.6 in the change in RH-PAT score from baseline to 12 weeks, we estimated that the study would need a sample size of 45 patients per treatment group to have 80% power at a two tailed alpha=0.05 level to detect a minimum difference in change in RH-PAT score of 0.36 between treatment groups.</population>
          <units>reactive hypermia index</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="-0.235" upper_limit="0.495"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-0.355" upper_limit="0.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inflammation -</title>
        <description>Median within subject change in hs-CRP levels between baseline and week 12 in active and placebo groups</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Ergocalciferal 50,000 U qweekly x 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation -</title>
          <description>Median within subject change in hs-CRP levels between baseline and week 12 in active and placebo groups</description>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" lower_limit="-1.82" upper_limit="1.48"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.96" upper_limit="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inflammation</title>
        <description>Median within subject change in interferon-gamma levels between baseline and week 12 in active and placebo groups</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ergocalciferol</title>
            <description>50,000 units of ergocalciferol once a week for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation</title>
          <description>Median within subject change in interferon-gamma levels between baseline and week 12 in active and placebo groups</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" lower_limit="-13.34" upper_limit="8.76"/>
                    <measurement group_id="O2" value="-2.8" lower_limit="-8.78" upper_limit="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inflammation</title>
        <description>Median within subject change in cxcl-10 .levels between baseline and week 12 in active and placebo groups</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Therapy</title>
            <description>Ergocalciferol 50,000 U q weekly x 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sugar Pill</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation</title>
          <description>Median within subject change in cxcl-10 .levels between baseline and week 12 in active and placebo groups</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.45" lower_limit="-27.35" upper_limit="12.45"/>
                    <measurement group_id="O2" value="-2.72" lower_limit="-15.12" upper_limit="9.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inflammation</title>
        <description>Median within subject change in IL-12 levels between baseline and week 12 in active and placebo groups</description>
        <time_frame>Baseline to week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ergocalciferol</title>
            <description>50,000 units of ergocalciferol once a week for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation</title>
          <description>Median within subject change in IL-12 levels between baseline and week 12 in active and placebo groups</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.96" lower_limit="-43.46" upper_limit="21.54"/>
                    <measurement group_id="O2" value="-2.33" lower_limit="-27.18" upper_limit="22.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ergocalciferol</title>
          <description>50,000 units of ergocalciferol once a week for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Matching placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Heart failure exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>ICD shock inappropriate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Atypical chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Seth I Sokol</name_or_title>
      <organization>Jacobi Medical Center</organization>
      <phone>718-918-5735</phone>
      <email>seth.sokol@nbhn.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

